<DOC>
	<DOCNO>NCT01205269</DOCNO>
	<brief_summary>The purpose study investigate effect inhale AZD8683 compare placebo COPD patient .</brief_summary>
	<brief_title>The Study Will Evaluate Effect AZD8683 Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description>A double-blind , placebo-controlled , randomised , multi-centre , 3-way cross-over , single-dose phase II study investigate local systemic effect inhale AZD8683 patient chronic obstructive pulmonary disease ( COPD )</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Clinical diagnosis COPD Current exsmokers FEV1 40 80 % predict normal value ( postbronchodilator ) postbronchodilator FEV1/FVC &lt; 70 % Any clinically significant disease disorder Any clinically relevant abnormal finding screen examination Family history presence glaucoma Need long term oxygen therapy</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease ( COPD )</keyword>
	<keyword>safety</keyword>
	<keyword>inhalation</keyword>
	<keyword>long-acting muscarinic receptor antagonist ( LAMA )</keyword>
</DOC>